Cranberry
Phase 1Small molecule
Cranberry is one of 4 small molecule programs targeting Crohn Disease (CD). It is currently in Phase 1.
1
Indications
5
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Crohn Disease (CD)
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonApproved
DB-3Q
DDirect Biologics, LLC
Phase 2
R-3750
RRise Therapeutics LLC
Phase 1
Cranberry
UUniversity of British Columbia
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urinary Tract Infection4 trials
Show 1 more trial
Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery
Active, not recruiting·—·N/A·NCT03522961·142 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cranberry. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of British Columbia